Anne Li May 13th, 2017
The researchers, led by UCLA's Dr. Antoni Ribas, studied how melanoma cancer cells react to the interferon gamma pathway, which guides cell signaling and can affect the way cancer cells react to pembrolizumab. The team then discovered and mapped out the molecules involved in this signaling pathway. The findings lay the groundwork for developing new and improved combination therapies for patients who are resistant to stand-alone immunotherapy treatments.
See original article at: https://www.sciencedaily.com/releases/2017/05/170509133051.htm